Company profile: Evox Therapeutics
1.1 - Company Overview
Company description
- Provider of engineered exosome-based delivery and therapeutics via its DeliverEX platform to modify exosomes, load drugs, and target delivery to specific organs. Solutions include treatments for rare diseases, exosome-enabled gene therapy (AAV cloaking), gene editing with CRISPR, RNA therapeutics, and precision targeting to the brain and central nervous system.
Products and services
- DeliverEX platform: Evox engineers a proprietary system that modifies exosomes, loads drug cargos, and targets delivery to specific organs by harnessing natural extracellular vesicle trafficking
- Gene Therapy: Evox constructs immune-evasive therapeutics by loading exosomes with AAV particles encoding therapeutic genes, aiming to cloak them from immune recognition and deliver gene payloads to target tissues
- Exosome-based therapeutics: Evox architects vesicle-mediated therapeutics using exosomes to treat life-threatening rare diseases, leveraging natural delivery capabilities of engineered extracellular vesicles.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Evox Therapeutics
Zymenex
HQ: Denmark
Website
- Description: Provider of novel enzyme replacement therapies for life-threatening, rare genetic diseases; a Scandinavian biopharmaceutical company developing and commercializing human recombinant enzymes for therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zymenex company profile →
Pharvaris
HQ: Switzerland
Website
- Description: Provider of oral bradykinin B2-receptor antagonist therapies in clinical development for hereditary angioedema (HAE), including deucrictibant; PHVS416 immediate-release capsules for acute HAE attacks; PHVS719 extended-release tablets for HAE prophylaxis; and the RAPIDe-1, RAPIDe-2, and CHAPTER-1 clinical trials evaluating these candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharvaris company profile →
HemoShear
HQ: United States
Website
- Description: Provider of the REVEAL-Tx platform, a drug discovery system combining biological and computational models to accelerate development of treatments for rare disorders. Offerings include HST5040, a clinical candidate for Propionic Acidemia and Methylmalonic Acidemia, and a human tissue-based model of rare liver disease developed in collaboration with Takeda.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HemoShear company profile →
Quellis Bio
HQ: United States
Website
- Description: Provider of next-generation antibody therapies aimed at improving outcomes for patients with serious rare diseases, focusing on discovering best-in-class new molecules to address underserved treatment needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quellis Bio company profile →
Acer Therapeutics
HQ: United States
Website
- Description: Provider of therapies for serious rare diseases, focused on acquiring, developing, and commercializing treatments. Portfolio includes OLPRUVA (U.S.-approved for urea cycle disorders) and investigational EDSIVO (vascular Ehlers-Danlos, COL3A1-positive), ACER-001 (Maple Syrup Urine Disease and other metabolic disorders), ACER-801 (vasomotor symptoms, PTSD), and ACER-2820 (host-directed therapy against viruses, incl. COVID-19).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acer Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Evox Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Evox Therapeutics
2.2 - Growth funds investing in similar companies to Evox Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Evox Therapeutics
4.2 - Public trading comparable groups for Evox Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →